Evidence map›Paper›PMID 40839414›Full record

Observational studyCancer2025

Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.

Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, Elena M Elli, Erika Morsia, Mirko Farina, Mario Tiribelli, Giulia Benevolo, Eloise Beggiato, Bruno Martino and 22 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06516406 (Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06516406 recruitingnot on this map

Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

Typeobservational_patient_registrySponsorIRCCS Azienda Ospedaliero-Universitaria di BolognaRan2022 to 2032Enrolled1,055ConditionsMyelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Review
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Francesca PalandriIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.ORCID https://orcid.org/0000-0001-8367-5668
Filippo BranzantiDipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
Massimiliano BonifacioDepartment of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy.ORCID https://orcid.org/0000-0003-0716-1686
Elena M ElliDivisione di Ematologia e Unità Trapianto di Midollo, IRCCS San Gerardo dei Tintori, Monza, Italy.ORCID https://orcid.org/0000-0001-5576-5412
Erika MorsiaHematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy.
Mirko FarinaDepartment of Clinical and Experimental Sciences, Unit of Blood Diseases and Stem Cells Transplantation, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy.ORCID https://orcid.org/0000-0002-2980-9028
Mario TiribelliDivision of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.ORCID https://orcid.org/0000-0001-9449-2621
Giulia BenevoloUniversity Hematology Division, Città della Salute e della Scienza Hospital, Torino, Italy.ORCID https://orcid.org/0000-0002-3200-9654
Eloise BeggiatoUnit of Hematology, Department of Oncology, University of Torino, Torino, Italy.
Bruno MartinoDivision of Hematology, Reggio Calabria, Azienda Ospedaliera "Bianchi Melacrino Morelli", Calabria, Italy.
Giovanni CaocciEmatologia, Ospedale Businco, Università degli studi di Cagliari, Cagliari, Italy.
Novella PuglieseDepartment of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.ORCID https://orcid.org/0000-0002-2714-5109
Alessia TieghiDepartment of Hematology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Monica CrugnolaHaematology and BMT Centre, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Gianni BinottoUnit of Hematology and Clinical Immunology, University of Padova, Padova, Italy.
Francesco CavazziniDivision of Hematology, University of Ferrara, Ferrara, Italy.
Elisabetta AbruzzeseDivision of Hematology, Ospedale S. Eugenio, Roma, Italy.ORCID https://orcid.org/0000-0001-5228-6491
Alessandro IsidoriHematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy.
Alessandra DedolaDipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
Emilia ScalzulliHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.
Andrea DuminucoUO Ematologia, AOU Policlinico "G. Rodolico"-San Marco, Catania, Italy.ORCID https://orcid.org/0000-0002-9510-4755
Luca TosoniDivision of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.
Alda StrazimiriDepartment of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy.
Roberto M LemoliDepartment of Internal Medicine (DiMI), Clinic of Hematology, University of Genoa, Genoa, Italy.
Daniela CilloniDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Monica BocchiaHematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy.
Fabrizio PaneDepartment of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.
Chiara SartorIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Florian H HeidelHematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.
Massimo BrecciaHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.ORCID https://orcid.org/0000-0003-1163-6162
Giuseppe A PalumboDepartment of Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy.
Andrew T KuykendallDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.ORCID https://orcid.org/0000-0002-9040-7415

Funding

Ministero della Salute RC-2024-2790083
6 · The paper itself

Abstract

backgroundThe response to ruxolitinib after 6 months (RR6) model allows early identification of ruxolitinib-treated myelofibrosis (MF) patients with poorer overall survival (OS); however, it is less applicable to lower-risk patients.

methodsTo further explore this, the authors performed a subanalysis of the "RUX-MF" study (NCT06516406) with an aim to validate the RR6 and to develop a score specific for intermediate-1 DIPSS/MYSEC-PM risk patients.

resultsAmong the 776 evaluable patients, 34.4%, 47.8%, and 17.8% were at low, intermediate, and high RR6 risk, with 5-year OS of 64.1%, 51.8%, and 44.5%, respectively (p < .001). In the 428 intermediate-1 patients, the RR6 model did not discriminate between intermediate and low-risk patients (5-year OS: 74.4% vs. 72.0%, p = .24). The intermediate-1 specific RR6 (iRR6) model was therefore developed by incorporating new variables: underdosed ruxolitinib with respect to platelet count at one or more time points (hazard ratio [HR], 3.91; p < .001), absence of palpable spleen reduction by ≥50% at 6 months (HR, 1.45; p = .02), and red blood cell transfusion requirement at all time points (HR, 1.85; p = .01). The iRR6 model stratified patients into three risk categories: low (score 0, 20.3%), intermediate (score 1-2, 45.8%), and high-risk (score >2, 33.9%), with 5-year OS of 84.8%, 76.4%, and 56.6%, respectively (p < .0001). The iRR6 model was validated in a cohort of 95 intermediate-1 risk patients from the Moffitt Cancer Center, yielding stratification into the same three risk categories, with 5-year OS of 83.3% (low-risk), 71.7% (intermediate-risk), and 54.5% (high-risk) (p = .01).

conclusionsThe iRR6 model provides a more refined tool for the identification of intermediate-1 MF patients who may benefit from early therapy shift.

Indexed as

Primary MyelofibrosisPyrazolesAgedAged, 80 and overFemaleHumansMaleMiddle AgedNitrilesPyrimidinesRisk AssessmentTreatment OutcomeNitrilesPyrazolesPyrimidinesruxolitinibintermediate‐1post‐ET myelofibrosispost‐PV myelofibrosisprimary myelofibrosisruxolitinibsurvival score

Identifiers

PMID40839414
PMCPMC12369922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.